Open Label, Dose Finding Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Trial Profile

Open Label, Dose Finding Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Atezolizumab (Primary) ; RG 6146 (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 14 Dec 2017 Planned End Date changed from 19 Sep 2019 to 23 Sep 2020.
    • 14 Dec 2017 Planned primary completion date changed from 19 Sep 2019 to 23 Sep 2020.
    • 02 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top